ATE355293T1 - Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten - Google Patents

Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten

Info

Publication number
ATE355293T1
ATE355293T1 AT02757132T AT02757132T ATE355293T1 AT E355293 T1 ATE355293 T1 AT E355293T1 AT 02757132 T AT02757132 T AT 02757132T AT 02757132 T AT02757132 T AT 02757132T AT E355293 T1 ATE355293 T1 AT E355293T1
Authority
AT
Austria
Prior art keywords
bicycloheptanes
aza
diseases
substituted
treatment
Prior art date
Application number
AT02757132T
Other languages
English (en)
Inventor
Donn G Wishka
Daniel Patrick Walker
Jeffrey W Corbett
Steven Charles Reitz
Mark R Rauckhorst
Vincent E Groppi Jr
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of ATE355293T1 publication Critical patent/ATE355293T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02757132T 2001-09-12 2002-09-04 Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten ATE355293T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32210001P 2001-09-12 2001-09-12
US32233301P 2001-09-12 2001-09-12
US32234601P 2001-09-12 2001-09-12
US39953002P 2002-07-30 2002-07-30

Publications (1)

Publication Number Publication Date
ATE355293T1 true ATE355293T1 (de) 2006-03-15

Family

ID=27502238

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02757132T ATE355293T1 (de) 2001-09-12 2002-09-04 Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten

Country Status (10)

Country Link
US (1) US20030105089A1 (de)
EP (1) EP1425286B1 (de)
JP (1) JP2005527472A (de)
AR (1) AR036779A1 (de)
AT (1) ATE355293T1 (de)
BR (1) BR0212477A (de)
CA (1) CA2460075A1 (de)
DE (1) DE60218493D1 (de)
MX (1) MXPA04002377A (de)
WO (1) WO2003022856A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
MXPA04008152A (es) * 2002-02-19 2005-09-08 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
BR0307874A (pt) 2002-02-20 2004-12-28 Upjohn Co Atividade de compostos azabicìclicos com receptor de acetilcolina nicotìnica alfa7
SK288115B6 (sk) 2002-09-25 2013-09-03 Memory Pharmaceuticals Corporation Indazoles, pharmaceutical compositions comprising them and their use
AU2003269413A1 (en) * 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
MXPA05004723A (es) * 2002-11-01 2005-12-05 Pharmacia & Upjohn Co Llc Compuestos que tienen ambas actividades del agonista alfa 7 nachr y el antagonista 5ht para el tratamiento de las enfermedades del snc.
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
US7273872B2 (en) 2002-12-06 2007-09-25 The Feinstein Institute For Medical Research Inhibition of inflammation using α 7 receptor-binding cholinergic agonists
JP2006518367A (ja) * 2003-02-21 2006-08-10 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー エキソ−（ｔ−ブチル２Ｒ（＋））−２−アミノ−７−アザビシクロ［２．２．１］ヘプタン−７−カルボキシレート、中間体、およびそれらを製造および単離する方法
WO2004091482A2 (en) * 2003-04-07 2004-10-28 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
GB0310867D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
JP4824578B2 (ja) 2003-12-22 2011-11-30 メモリー・ファーマシューティカルズ・コーポレイション インドール類、１，２−ベンズイソオキサゾール類、および１，２−ベンゾイソチアゾール類、ならびにそれらの製造と使用
US20050171079A1 (en) * 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
MXPA06010852A (es) 2004-03-25 2007-01-16 Memory Pharm Corp Indazoles, benzotiazoles, benzoisotiazoles, bencisoxazoles y preparacion y usos de los mismos.
WO2006001894A1 (en) * 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
KR20070015607A (ko) 2004-05-07 2007-02-05 메모리 파마슈티칼스 코포레이션 1ｈ-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그의 제조법 및 용도
CA2591817A1 (en) 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
NZ575512A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
JP2009507024A (ja) * 2005-09-01 2009-02-19 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害剤化合物およびその使用方法
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
BRPI0619989A2 (pt) * 2005-12-15 2011-10-25 Hoffmann La Roche Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, métodos para o tratamento e/ou prevenção de enfermidades que estão associados com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos
JP2009529047A (ja) 2006-03-07 2009-08-13 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環系ピラゾール化合物およびその使用
CA2674237C (en) 2006-12-28 2015-11-24 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8697722B2 (en) * 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
ES2552733T3 (es) 2007-11-16 2015-12-01 Rigel Pharmaceuticals, Inc. Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
US8129390B2 (en) 2007-12-12 2012-03-06 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds and methods for using the same
BRPI0911681B8 (pt) 2008-04-23 2021-05-25 Rigel Pharmaceuticals Inc composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro
US20100035862A1 (en) * 2008-06-25 2010-02-11 Abbott Laboratories Novel aza-cyclic indole-2-carboxamides and methods of use thereof
MY173229A (en) 2008-11-19 2020-01-07 Forum Pharmaceuticals Inc Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US8431595B2 (en) 2009-08-20 2013-04-30 The University Of Tennessee Research Foundation Furanopyridine cannabinoid compounds and related methods of use
RU2560729C2 (ru) * 2010-01-11 2015-08-20 АСТРАЕА ТЕРАПЕУТИКС, ЭлЭлСи Модуляторы никотиновых ацетилхолиновых рецепторов
PT3029039T (pt) 2010-05-17 2017-11-28 Forum Pharmaceuticals Inc Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado
WO2012082746A2 (en) * 2010-12-13 2012-06-21 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2846796A4 (de) 2012-05-08 2015-10-21 Forum Pharmaceuticals Inc Verfahren zur aufrechterhaltung, behandlung oder verbesserung der kognitiven funktion
EP2876109A4 (de) * 2012-07-23 2016-03-16 Yuhan Corp Kondensierte ringverbindung mit furan-oder einem salz davon sowie pharmazeutische zusammensetzungen damit
US10154992B2 (en) 2016-07-12 2018-12-18 The Regents Of The University Of California Compounds and methods for treating HIV infection
JP7434285B2 (ja) * 2018-08-14 2024-02-20 アムジエン・インコーポレーテツド Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用
JP2023553269A (ja) * 2020-11-18 2023-12-21 エランコ・ティアゲゾンタイト・アーゲー イヌ糸状虫感染症を治療するためのｎ－（２，３－ジヒドロ－１，４－ベンゾオキサジン－４－イル）－３－イソプロピル－７－（２，３，５－トリフルオロフェニル）ベンゾ－チオフェン－２－カルボキサミド誘導体及び類似化合物

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612319A (en) * 1982-04-14 1986-09-16 Beecham Group P.L.C. Bridged quinolizidinylbenzamides, compositions containing them and methods for their use
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
JPS5936675A (ja) * 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
DE3429830A1 (de) * 1983-08-26 1985-03-07 Sandoz-Patent-GmbH, 7850 Lörrach Automatische carbonsaeure- und sulfonsaeureester oder -amide
US5175173A (en) * 1983-12-22 1992-12-29 Sun Jung Hui Carboxamides useful as antiemetic or antipsychotic agents
US4888353A (en) * 1986-02-28 1989-12-19 Erbamont, Inc. Carboxamides useful as antiemetic or antipsychotic agents
US5122528A (en) * 1983-12-22 1992-06-16 Erbamont, Inc. Analgesic use of benzobicyclic carboxamides
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE3689974T2 (de) * 1985-03-14 1994-11-03 Beecham Group Plc Arzneimittel zur Behandlung von Emesis.
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8520616D0 (en) * 1985-08-16 1985-09-25 Beecham Group Plc Compounds
US4910193A (en) * 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE3782107T2 (de) * 1986-07-25 1993-04-01 Beecham Group Plc Azabicyclische verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
NL8701682A (nl) * 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
DE3752062T2 (de) * 1986-12-17 1997-09-11 Glaxo Group Ltd Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln
DE3788057T2 (de) * 1986-12-17 1994-03-03 Glaxo Group Ltd Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
US5322951A (en) * 1987-01-05 1994-06-21 Beecham Group, P.L.C. Certain 1-(2,3-dihydro-indole)carbonyl intermediates
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
US4835162A (en) * 1987-02-12 1989-05-30 Abood Leo G Agonists and antagonists to nicotine as smoking deterents
DE3852145T2 (de) * 1987-02-18 1995-04-06 Beecham Group Plc Indolderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten.
DE3881950T2 (de) * 1987-04-25 1993-09-30 Beecham Group Plc Azabicyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US4921982A (en) * 1988-07-21 1990-05-01 Eli Lilly And Company 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
CA1304082C (en) * 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
IE63474B1 (en) * 1987-12-24 1995-04-19 Wyeth John & Brother Ltd Heterocyclic compounds
US5246942A (en) * 1988-04-27 1993-09-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Pharmaceutically useful dibenzofurancarboxamides of specific stereo-configuration
EP0350130A3 (de) * 1988-07-07 1991-07-10 Duphar International Research B.V Substituierte 1,7-annelierte 1H-Indazole
US4933445A (en) * 1988-11-29 1990-06-12 Rorer Pharmaceutical Corporation Heteroazabenzobicyclic carboxamide 5-HT3 antagonists
US4920227A (en) * 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Benzobicyclic carboxamide 5-HT3 antagonists
US4920219A (en) * 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents
EP0402056A3 (de) * 1989-06-06 1991-09-04 Beecham Group p.l.c. Azabicyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US5185333A (en) * 1989-07-03 1993-02-09 Yoshitomi Pharmaceutical Industries, Ltd. Benzazine compounds and pharmaceutical uses thereof
US4935511A (en) * 1989-09-26 1990-06-19 Rorer Pharmaceutical Corporation Benzoxazine and benzoxazepine carboxamide 5-HT3 antagonists
GB2236751B (en) * 1989-10-14 1993-04-28 Wyeth John & Brother Ltd Heterocyclic compounds
CA2090037A1 (en) * 1990-08-31 1992-03-01 Shoichi Chokai Indole derivatives and drugs
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
MX9102686A (es) * 1990-12-27 1994-01-31 Erba Carlo Spa Carboxamidas de dihidrobenzofurano y proceso para su preparacion.
US5114947A (en) * 1990-12-27 1992-05-19 Erbamont Inc. Method for alleviating anxiety using benzobicyclic carboxamides
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
JPH05310732A (ja) * 1992-03-12 1993-11-22 Mitsubishi Kasei Corp シンノリン−３−カルボン酸誘導体
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
US5273972A (en) * 1992-03-26 1993-12-28 A. H. Robins Company, Incorporated [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
SE9201478D0 (sv) * 1992-05-11 1992-05-11 Kabi Pharmacia Ab Heteroaromatic quinuclidinenes, their use and preparation
US5300512A (en) * 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US6060473A (en) * 1993-04-01 2000-05-09 Ucb S.A. - Dtb 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands
US6117889A (en) * 1994-04-01 2000-09-12 University Of Virginia 7-Azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents
US5510486A (en) * 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US5510478A (en) * 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5723103A (en) * 1994-12-09 1998-03-03 Vanderbilt University Substituted benzamides and radioligand analogs and methods of use
EP0812840A4 (de) * 1995-03-02 1999-02-10 Yamanouchi Pharma Co Ltd Neue chinuclidin-derivate mit tricyclischem kundensierten heteroring
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
AR036779A1 (es) 2004-10-06
JP2005527472A (ja) 2005-09-15
CA2460075A1 (en) 2003-03-20
MXPA04002377A (es) 2004-11-22
EP1425286B1 (de) 2007-02-28
WO2003022856A1 (en) 2003-03-20
US20030105089A1 (en) 2003-06-05
DE60218493D1 (de) 2007-04-12
BR0212477A (pt) 2004-08-24
EP1425286A1 (de) 2004-06-09

Similar Documents

Publication Publication Date Title
ATE355293T1 (de) Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten
ATE502642T1 (de) Kombinationen für die behandlung von immun- entzündlichen erkrankungen
DE60124576D1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
ATE439844T1 (de) Kombinationen für die behandlung entzündlicher erkrankungen
DE60316538D1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
DE69927823D1 (de) Hydrogel für die therapeutische behandlung von aneurysmas
ATE441417T1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
DE69829558D1 (de) Sulfonamide für die behandlung von störungen durch endothelin vermittelt
DE60226702D1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE60233069D1 (de) Zusammensetzungen aus curcuma extrakten für die behandlung von neurozerebrovaskulären erkrankungen
EP0792137A4 (de) Pilzhemmende behandlung für die nägel
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
EP1513403A4 (de) Herzglykoside für die behandlung von mukoviszidose und anderen il-8-bedingten erkrankungen
DE60325498D1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
ATE276262T1 (de) Oxazinochinolone für die behandlung viraler infektionen
DE69533876D1 (de) Zusammensetzung für die gentherapeutische Behandlung von Koronar-Arterienerkrankungen.
DE69622889D1 (de) Substituierte 4-(1h-benzimidazol-2-yl)(1,4)diazepane für die behandlung von allergischen krankheiten
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
ATE391507T1 (de) S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie
DE60218529D1 (de) Isochroman verbindungen für die behandlung von cns-krankheiten
ATE253556T1 (de) Aminoacylaroylpyrrole für die behandlung des neuropathischen schmerzes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties